
Myung Sun Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3373394/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. Leukemia and Lymphoma, 2023, 64, 722-724.	1.3	1
2	When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100. BMJ Evidence-Based Medicine, 2022, 27, 151-152.	3.5	1
3	Artificial intelligence and magnetic resonance imaging may not make cancer screening better. Journal of Cancer Policy, 2022, 31, 100314.	1.4	0
4	Overall survival for oncology drugs approved for genomic indications. European Journal of Cancer, 2022, 160, 175-179.	2.8	6
5	Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia. Case Reports in Hematology, 2022, 2022, 1-5.	0.4	5
6	Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. Blood Advances, 2022, 6, 1207-1211.	5.2	12
7	Quality of biomarker defined subgroups in <scp>FDA</scp> approvals of <scp>PD</scp> â€1/ <scp>PDâ€L1</scp> inhibitors 2014 to 2020. International Journal of Cancer, 2022, 150, 1905-1910.	5.1	3
8	Addressing Sex Disparities in Academic Oncology. JAMA Oncology, 2022, , .	7.1	0
9	Persistent challenges with treating multiple myeloma early. Blood, 2021, 137, 456-458.	1.4	17
10	Approval and Coverage of Cancer Drugs in England, Canada, and the US. JAMA Internal Medicine, 2021, 181, 509.	5.1	7
11	Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. European Journal of Cancer, 2021, 155, 163-167.	2.8	7
12	Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature. JAMA Internal Medicine, 2021, , .	5.1	5
13	New drugs and options can enhance patient outcomes: But can they also erode them?. European Journal of Cancer, 2021, 154, 1-3.	2.8	1
14	A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy. Blood, 2021, 138, 184-184.	1.4	1
15	The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. JAMA Internal Medicine, 2020, 180, 315.	5.1	5
16	US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation. Cancer, 2020, 126, 4270-4272.	4.1	3
17	Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals. JAMA Network Open, 2019, 2, e193981.	5.9	7
18	Cancer screening: A modest proposal for prevention. Cleveland Clinic Journal of Medicine, 2019, 86, 157-160.	1.3	3